7774 Stock Overview
Engages in the regenerative medicine business in Japan. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 7774 from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Japan Tissue Engineering Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥441.00 |
| 52 Week High | JP¥811.00 |
| 52 Week Low | JP¥430.00 |
| Beta | 0.40 |
| 1 Month Change | -11.27% |
| 3 Month Change | -14.86% |
| 1 Year Change | -8.32% |
| 3 Year Change | -20.97% |
| 5 Year Change | -54.54% |
| Change since IPO | 11.93% |
Recent News & Updates
Shareholder Returns
| 7774 | JP Biotechs | JP Market | |
|---|---|---|---|
| 7D | -5.8% | -2.0% | -0.02% |
| 1Y | -8.3% | 20.2% | 14.6% |
Return vs Industry: 7774 underperformed the JP Biotechs industry which returned 20.2% over the past year.
Return vs Market: 7774 underperformed the JP Market which returned 14.6% over the past year.
Price Volatility
| 7774 volatility | |
|---|---|
| 7774 Average Weekly Movement | 2.5% |
| Biotechs Industry Average Movement | 6.8% |
| Market Average Movement | 3.6% |
| 10% most volatile stocks in JP Market | 7.3% |
| 10% least volatile stocks in JP Market | 1.9% |
Stable Share Price: 7774 has not had significant price volatility in the past 3 months compared to the JP market.
Volatility Over Time: 7774's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 211 | Ken-Ichiro Hata | www.jpte.co.jp |
Japan Tissue Engineering Co., Ltd. engages in the regenerative medicine business in Japan. The company operates through Regenerative Medicine Product, Regenerative Medicine Outsourcing, and Research and Development Support segments. It offers autologous cultured epidermis, cartilage, corneal epithelium, and oral mucosal epithelium to medical institutions for the purpose of medical treatment.
Japan Tissue Engineering Co., Ltd. Fundamentals Summary
| 7774 fundamental statistics | |
|---|---|
| Market cap | JP¥17.99b |
| Earnings (TTM) | -JP¥71.00m |
| Revenue (TTM) | JP¥2.43b |
7.4x
P/S Ratio-252.2x
P/E RatioIs 7774 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7774 income statement (TTM) | |
|---|---|
| Revenue | JP¥2.43b |
| Cost of Revenue | JP¥892.00m |
| Gross Profit | JP¥1.54b |
| Other Expenses | JP¥1.61b |
| Earnings | -JP¥71.00m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Jan 31, 2025
| Earnings per share (EPS) | -1.75 |
| Gross Margin | 63.28% |
| Net Profit Margin | -2.92% |
| Debt/Equity Ratio | 0% |
How did 7774 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 14:34 |
| End of Day Share Price | 2024/12/25 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Japan Tissue Engineering Co., Ltd. is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hidemaru Yamaguchi | Citigroup Inc |
| Kiyokazu Yamazaki | Ichiyoshi Research Institute Inc. |
| Shigekazu Ishida | Marusan Securities Co. Ltd. |